12 New Drugs in 2017

 

In 2017, FDA (Food and Drug Administration) approved 46 new drugs, breaking the record of most approved new drugs in 66 years in 2015 (45 new drugs). 2017 was a bumper harvest year in the pharmaceutical industry coupled with newly approved biological products. The FirstWord website summarizes and analyzes the most noteworthy products. 

 

1. Dupixent: Potential to be dug

Indication: Atopic Dermatitis

Enterprise: RGEN/Sanofi

 

2. Hemlibra: Reshape the market pattern

Indication: Hemophilia A

Enterprise: Roche

 

3. Kymriah: Start the first battle of CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy)

Indication: Acute Lymphoblastic Leukemia

Enterprise: Novartis

 

4. Yescarta: Start the first battle of CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy)

Indication: Diffuse Large B Cell Lymphoma

Enterprise: Gilead

 

5. Luxturna: Widespread concerns about its pricing

Indication: Retinal Dystrophy

Enterprise: Spark

 

 

6. Ocrevus: Strong performance

Indication: Multiple Sclerosis

Enterprise: Roche

 

7. Ozempic: Regarded as the future pillar of the company

Indication: Diabetes

Enterprise: Novo Nordisk

 

8. Rydapt: Make breakthrough progress in the treatment of AML

Indication: Acute Myelogenous Leukemia

Enterprise: Novartis

 

9. Idhifa: Make breakthrough progress in the treatment of AML

Indication: Acute Myelogenous Leukemia

Enterprise: CELG/Agios

 

10. Shingrix: The motivation of GSK performance growth

Indication: Herpes Zoster Vaccine

Enterprise: GlaxoSmithKline

 

11. Tremfya: The strong challenge of the latecomer

Indication: Psoriasis

Enterprise: Johnson & Johnson

 

12. Zejula: Set up two industry benchmarks in PARP inhibitors

Indication: Ovarian Cancer

Enterprise: Tesaro